Eli Lilly & Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $79.7B+76.9% YoYTTM through 30 Jun 2026
Net Income $26.7B+152.2% YoYTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 44.8% |
| Operating Margin | 42.2% |
| Net Margin | 33.5% |
Returns
78.8%ROE
18.8%ROA
33.5%ROIC
Balance Sheet Health
Debt / Equity1.62x
Current Ratio1.35x
Net Debt$46B
Cash & Equivalents$9B
Quality Metrics
Altman Z-Score7.57
Piotroski F-Score6 / 9
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $65.2B
Diluted EPS$29.79TTMFY2025: $22.95
Dividend
$3.46Per share, FY20260.30%Yield+0.4%5-yr growth
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Human Pharmaceutical Products | $65.2B | +44.7% | View detailsLilly forecasts full-year 2026 revenue to be between $80.0 billion and $83.0 billion, driven by continued global demand for its incretin portfolio. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.